Omics · study · 2026
SPLEVs, a new therapeutic modality for cytokine storm syndromes
Listed in NCBI GEO
Since cytokine storm syndromes such as sepsis, acute respiratory distress syndrome (ARDS) and coagulopathy, including those seen in COVID-19, are fatal, development of highly effective therapeutics is urgently needed.
Description
We previously reported that the hydrolysis of extracellular vesicles (EVs) by secreted phospholipase A2 (sPLA2) leads to production of immunomodulatory lipid mediators in lymphoproliferative diseases. We aimed to apply this phenomenon technically using sPLA2-reacted EVs — here in designated as “SPLEVs”, which showed high therapeutic efficacies against various disease.
Mechanistically, SPLEVs bind to type II alveolar epithelial cells and elicit “lipid counterstorm”, drastically increasing the production of tissue-protective and anti-inflammatory lipid mediators through the phosphoinositide 3-kinase and sterol regulatory element-binding protein 1 pathways. And these effects showed an important role of PG in hep-EVs, and Lyso-PG hydrolyzed by sPLA2 was involved in the regulation of inflammation.
Read the rest (1 more)
Also, hep-SPLEVs injection showed increased lipid mediators and anti-inflammatory effects in inflammatory diseases other than ARDS, prolonged survival and reduced tissue damage. Thus, SPLEVs are expected to be an effective therapeutic tool for treatment of broad ranges of inflammatory diseases including COVID-19 and other new pandemic diseases.
Links
Get the data
- GEO FTP directory ftp.ncbi.nlm.nih.gov/geo/series/GSE294nnn/GSE294641 ↗
download · from NCBI GEO
Where it is published
- GEO accession page ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294641 ↗
landing page · from NCBI GEO
Documentation and papers
- PRJNA1251004 ncbi.nlm.nih.gov/bioproject/PRJNA1251004 ↗
project · from NCBI GEO
- PubMed 42536729 pubmed.ncbi.nlm.nih.gov/42536729 ↗
publication · from NCBI GEO
Topics
- Stated by source
- Expression profiling by high throughput sequencing · Mus musculus
- From keywords
- Life Sciences
- Inferred from text
- Disease 75%
Provenance · 1 source records, 8 field assertions
| Source | Key | Last seen | Raw |
|---|---|---|---|
| NCBI GEO | GSE294641 | 13 d ago | JSON v1 |
| Field | Assertion | Extractor | Evidence |
|---|---|---|---|
| access_level | source · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| concepts[disease].local:disease:disease | enrichment · NCBI GEO | keyword-concept-rules@1.0.0 | title+description (75%) |
| concepts[field].local:field:life-sciences | mapping · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| concepts[method].geo_series_type:expression-profiling-by-high-throughput-sequencing | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /gdstype |
| concepts[organism].NCBITaxon:10090 | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /taxon |
| description | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /summary |
| publication_date | source · NCBI GEO | connector:ncbi_geo@1.0.0 | |
| title | source · NCBI GEO | connector:ncbi_geo@1.0.0 | /title |